Vc Thoughts, Health, Dna, Rna, Healthcare.
Expensive manufacturing One of the most significant hurdles for LNP and AAV-based therapies is the manufacturing process, particularly when considering scalable production. For LNPs, the high costs are associated with the availability of GMP reagents (e.g. 5’ capping enzyme and lipids), keeping